Huntsman CORP (HUN) · Aug 17, 2026 · Acquisition
Merger supplement — No merger-term change; two Huntsman complaints and one Olin complaint disclosed
Huntsman supplements its Olin merger proxy after stockholder lawsuits, but leaves deal terms, outlook and board recommendation intact.
The transaction was already largely known, and this filing does not change its economics. Huntsman and Olin had already signed the merger agreement, made the registration statement effective, and scheduled both shareholder meetings for August 25, 2026. The new filing is primarily a supplemental proxy disclosure intended to reduce litigation and delay risk, not a revised offer or new transaction structure. Huntsman said it “voluntarily amends and supplements the Joint Proxy Statement/Prospectus” (Supplemental disclosures) 〔0〕
The main negative is additional deal-process friction, not evidence that the merger’s underlying value has deteriorated. Two lawsuits from purported Huntsman stockholders and one from purported Olin shareholders allege disclosure omissions, with plaintiffs seeking corrective disclosures and potentially to delay the vote or merger. (Litigation disclosures) 〔1〕 (Litigation disclosures) 〔2〕
The supplemental material mostly adds valuation mechanics and confirms that Huntsman’s standalone operating outlook was stable. The updated projections cut 2026 revenue by $137 million but left 2027–2030 revenue unchanged and reduced only 2029E and 2030E adjusted EBITDA by $1 million each. (Huntsman standalone projections)
| Disclosed item | Huntsman | Olin |
|---|---|---|
| Citi DCF implied equity value per share (Financial analyses — Citi) | $15.20–$21.80 | $41.40–$56.30 |
| Selected-company 2026E adjusted EBITDA (Financial analyses — Citi) | $346 million | — |
| Selected-company 2027E adjusted EBITDA (Financial analyses — Citi) | $501 million | — |
| Net debt / other items used by Lazard (Financial analyses — Lazard) | $1.908 billion | $2.804 billion |
| Fully diluted shares used by Lazard (Financial analyses — Lazard) | 178.068–178.241 million | 117.506–117.961 million |
Net, this is a mildly mixed procedural update: litigation risk increases modestly, but the absence of deal-term changes, unchanged board support and largely stable projections leave the merger thesis intact. The board continues to unanimously recommend approval (Board recommendation) 〔3〕
August 25 special meetings
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!